313 related articles for article (PubMed ID: 25194568)
1. A new tumor suppressor role for the Notch pathway in bladder cancer.
Rampias T; Vgenopoulou P; Avgeris M; Polyzos A; Stravodimos K; Valavanis C; Scorilas A; Klinakis A
Nat Med; 2014 Oct; 20(10):1199-205. PubMed ID: 25194568
[TBL] [Abstract][Full Text] [Related]
2. NOTCH pathway inactivation promotes bladder cancer progression.
Maraver A; Fernandez-Marcos PJ; Cash TP; Mendez-Pertuz M; Dueñas M; Maietta P; Martinelli P; Muñoz-Martin M; Martínez-Fernández M; Cañamero M; Roncador G; Martinez-Torrecuadrada JL; Grivas D; de la Pompa JL; Valencia A; Paramio JM; Real FX; Serrano M
J Clin Invest; 2015 Feb; 125(2):824-30. PubMed ID: 25574842
[TBL] [Abstract][Full Text] [Related]
3. Canonical Notch signalling is inactive in urothelial carcinoma.
Greife A; Jankowiak S; Steinbring J; Nikpour P; Niegisch G; Hoffmann MJ; Schulz WA
BMC Cancer; 2014 Aug; 14():628. PubMed ID: 25167871
[TBL] [Abstract][Full Text] [Related]
4. The NOTCH pathway plays a tumor suppressive role in bladder cancer.
Cancer Discov; 2014 Nov; 4(11):1252. PubMed ID: 25367939
[TBL] [Abstract][Full Text] [Related]
5. Notch-1 regulates proliferation and differentiation of human bladder cancer cell lines by inhibiting expression of Krüppel-like factor 4.
Ai X; Jia Z; Liu S; Wang J; Zhang X
Oncol Rep; 2014 Oct; 32(4):1459-64. PubMed ID: 25109409
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer and the Notch pathway.
Fernandez-Marcos PJ; Serrano M; Maraver A
Oncotarget; 2015 Jan; 6(3):1346-7. PubMed ID: 25633811
[No Abstract] [Full Text] [Related]
7. A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes.
Giachino C; Boulay JL; Ivanek R; Alvarado A; Tostado C; Lugert S; Tchorz J; Coban M; Mariani L; Bettler B; Lathia J; Frank S; Pfister S; Kool M; Taylor V
Cancer Cell; 2015 Dec; 28(6):730-742. PubMed ID: 26669487
[TBL] [Abstract][Full Text] [Related]
8. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
9. Consequences of Disrupted Notch Signaling in Bladder Cancer.
Greife A; Hoffmann MJ; Schulz WA
Eur Urol; 2015 Jul; 68(1):3-4. PubMed ID: 25791514
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
11. Unravelling disparate roles of NOTCH in bladder cancer.
Goriki A; Seiler R; Wyatt AW; Contreras-Sanz A; Bhat A; Matsubara A; Hayashi T; Black PC
Nat Rev Urol; 2018 Jun; 15(6):345-357. PubMed ID: 29643502
[TBL] [Abstract][Full Text] [Related]
12. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
di Martino E; Alder O; Hurst CD; Knowles MA
Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer.
Schulz GB; Elezkurtaj S; Börding T; Schmidt EM; Elmasry M; Stief CG; Kirchner T; Karl A; Horst D
Cancer Sci; 2021 May; 112(5):1987-1996. PubMed ID: 33686706
[TBL] [Abstract][Full Text] [Related]
14. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of the role and relationship between Notch-1 and Oct-4 expression in urinary bladder carcinoma.
Abdou AG; El-Wahed MM; Kandil MA; Samaka RM; Elkady N
APMIS; 2013 Oct; 121(10):982-96. PubMed ID: 23594289
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Hoffman KL; Lerner SP; Smith CL
Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
[TBL] [Abstract][Full Text] [Related]
17. Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.
Swellam M; El-Aal AA; AbuGabel KM
Clin Biochem; 2004 Dec; 37(12):1098-104. PubMed ID: 15589816
[TBL] [Abstract][Full Text] [Related]
18. Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?
Zhang M; Biswas S; Qin X; Gong W; Deng W; Yu H
Cancer Med; 2016 Aug; 5(8):2048-60. PubMed ID: 27228302
[TBL] [Abstract][Full Text] [Related]
19. Notch controls urothelial integrity in the mouse bladder.
Paraskevopoulou V; Bonis V; Dionellis VS; Paschalidis N; Melissa P; Chavdoula E; Vasilaki E; Pateras IS; Klinakis A
JCI Insight; 2020 Feb; 5(3):. PubMed ID: 32051338
[TBL] [Abstract][Full Text] [Related]
20. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway.
Yu C; Zhang Z; Liao W; Zhao X; Liu L; Wu Y; Liu Z; Li Y; Zhong Y; Chen K; Li J; Zhou F; Song L
Carcinogenesis; 2012 Mar; 33(3):678-86. PubMed ID: 22223847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
